{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:24:25Z","timestamp":1778520265691,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Basic Scientific Research Projects of Wenzhou Science and Technology Bureau","award":["No.Y20210747"],"award-info":[{"award-number":["No.Y20210747"]}]},{"name":"Medicine and Health Science and Technology Plan Projects in Zhejiang Province","award":["No. 2024XY044"],"award-info":[{"award-number":["No. 2024XY044"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma (MM) denotes a cancerous growth characterized by abnormal proliferation of plasma cells. Growing evidence suggests that the complexity in addressing MM lies in the presence of minimal residual disease (MRD) within the body. MRD assessment is becoming increasingly important for risk assessment in patients with MM. Similarly, the levels of serum free protein light chain and their ratio play a crucial role in assessing the disease burden and changes in MM. In this paper, we review and explore the utilization of MRD and serum free light chain ratio in the treatment of MM, delving into their respective characteristics, advantages, disadvantages, and their interrelation.<\/jats:p>","DOI":"10.1007\/s12672-024-01090-1","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T02:01:37Z","timestamp":1718416897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The role of minimal residual disease and serum free light chain ratio in the management of multiple myeloma"],"prefix":"10.1007","volume":"15","author":[{"given":"Long-Ying","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-Lei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuo-Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,15]]},"reference":[{"issue":"3","key":"1090_CR1","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/leu.2015.223","volume":"30","author":"S Lonial","year":"2016","unstructured":"Lonial S, Durie B, Palumbo A, San-Miguel J. Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. Leukemia. 2016;30(3):526\u201335.","journal-title":"Leukemia"},{"issue":"6","key":"1090_CR2","first-page":"373","volume":"95","author":"TC Michels","year":"2017","unstructured":"Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. Am Fam Phys. 2017;95(6):373\u201383.","journal-title":"Am Fam Phys"},{"issue":"8","key":"1090_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40364-020-00192-6","volume":"13","author":"L Kang","year":"2020","unstructured":"Kang L, Zhang J, Li M, Xu N, Qi W, Tan J, et al. Characterization of novel dual tandem CD19\/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma. Biomark Res. 2020;13(8):14.","journal-title":"Biomark Res"},{"issue":"1","key":"1090_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cyto.b.21272","volume":"90","author":"AC Rawstron","year":"2016","unstructured":"Rawstron AC, Paiva B, Stetler-Stevenson M. Assessment of minimal residual disease in myeloma and the need for a consensus approach. Cytometry B Clin Cytom. 2016;90(1):21\u20135.","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"1090_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/bjh.15075","volume":"181","author":"Y Bai","year":"2018","unstructured":"Bai Y, Orfao A, Chim CS. Molecular detection of minimal residual disease in multiple myeloma. Br J Haematol. 2018;181(1):11\u201326.","journal-title":"Br J Haematol."},{"issue":"3","key":"1090_CR6","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s00259-015-3200-9","volume":"43","author":"C Nanni","year":"2016","unstructured":"Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, et al. Image interpretation criteria for FDG PET\/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2016;43(3):414\u201321.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"10","key":"1090_CR7","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garc\u00eda-S\u00e1nchez O, B\u00f6ttcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094\u2013103.","journal-title":"Leukemia"},{"issue":"7","key":"1090_CR8","first-page":"584","volume":"40","author":"PY Yang","year":"2019","unstructured":"Yang PY, Liu MM, Fan HQ, Yang YP, Han W, Yu XY, et al. The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma. Zhonghua Xue Ye Xue Za Zhi. 2019;40(7):584\u20138.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"23","key":"1090_CR9","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.1182\/blood.V128.22.4527.4527","volume":"128","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D, Korde NS, Roschewski M. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) followed by 2 years of lenalidomide maintenance (CRd-R): updated results of a phase 2 study. Blood. 2016;128(23):4527.","journal-title":"Blood"},{"issue":"12","key":"1090_CR10","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","volume":"1","author":"M Roshal","year":"2017","unstructured":"Roshal M, Flores-Montero JA, Gao Q, Koeber M, Wardrope J, Durie BGM, et al. MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. Blood Adv. 2017;1(12):728\u201332.","journal-title":"Blood Adv"},{"issue":"34","key":"1090_CR11","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1200\/JCO.20.00948","volume":"38","author":"AP Kater","year":"2020","unstructured":"Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D\u2019Rozario J, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol. 2020;38(34):4042\u201354.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1090_CR12","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood.2021011101","volume":"139","author":"M Cavo","year":"2022","unstructured":"Cavo M, San-Miguel J, Usmani SZ, Weisel K, Dimopoulos MA, Avet-Loiseau H, et al. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022;139(6):835\u201344.","journal-title":"Blood"},{"issue":"4","key":"1090_CR13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1200\/JCO.18.01580","volume":"37","author":"AP Kater","year":"2019","unstructured":"Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, et al. Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019;37(4):269\u201377.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1090_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40364-021-00328-2","volume":"9","author":"H Ding","year":"2021","unstructured":"Ding H, Xu J, Lin Z, Huang J, Wang F, Yang Y, et al. Minimal residual disease in multiple myeloma: current status. Biomark Res. 2021;9(1):75. https:\/\/doi.org\/10.1186\/s40364-021-00328-2.","journal-title":"Biomark Res"},{"issue":"3","key":"1090_CR15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nrclinonc.2018.6","volume":"15","author":"D Romero","year":"2018","unstructured":"Romero D. Haematological cancer: Improved sensitivity in MRD detection. Nat Rev Clin Oncol. 2018;15(3):134. https:\/\/doi.org\/10.1038\/nrclinonc.2018.6.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"1090_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/cyto.b.21862","volume":"98","author":"KT Soh","year":"2020","unstructured":"Soh KT, Tario JD Jr, Hahn TE, Hillengass J, McCarthy PL, Wallace PK. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease. Cytometry B Clin Cytom. 2020;98(2):161\u201373. https:\/\/doi.org\/10.1002\/cyto.b.21862.","journal-title":"Cytometry B Clin Cytom"},{"issue":"7","key":"1090_CR17","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1080\/10408363.2023.2209652","volume":"60","author":"C Wijnands","year":"2023","unstructured":"Wijnands C, Noori S, Donk NW, VanDuijn MM, Jacobs JF. Advances in minimal residual disease monitoring in multiple myeloma. Crit Rev Clin Lab Sci. 2023;60(7):518\u201334. https:\/\/doi.org\/10.1080\/10408363.2023.2209652.","journal-title":"Crit Rev Clin Lab Sci."},{"issue":"2","key":"1090_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.11735\/j.issn.1671-170X.2020.02.B005","volume":"26","author":"Y Lin","year":"2020","unstructured":"Lin Y, Wan SG. Application of multiparameter flow cytometry immunophenotyping analysis in the diagnosis and treatment of multiple myeloma. J Oncol. 2020;26(2):102\u20135. https:\/\/doi.org\/10.11735\/j.issn.1671-170X.2020.02.B005.","journal-title":"J Oncol"},{"issue":"5","key":"1090_CR19","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3760\/cma.j.issn.0253-2727.2018.05","volume":"39","author":"SH Deng","year":"2018","unstructured":"Deng SH, Xu Y, Sui WW. Clinical observation of multiparameter flow cytometry detection of minimal residual disease in 106 patients with multiple myeloma. Chin J Hematol. 2018;39(5):376\u201381. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2018.05.","journal-title":"Chin J Hematol"},{"issue":"4","key":"1090_CR20","doi-asserted-by":"publisher","first-page":"226","DOI":"10.18502\/ijhoscr.v14i4.4475","volume":"14","author":"R Benson","year":"2020","unstructured":"Benson R, Nair SG, Narayanan G. Early normalization of free light chains predicts better outcomes in patients with multiple myeloma. Int J Hematol Oncol Stem Cell Res. 2020;14(4):226\u201331. https:\/\/doi.org\/10.18502\/ijhoscr.v14i4.4475.","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"6","key":"1090_CR21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/PAT.0000000000000316","volume":"47","author":"SC Sasson","year":"2015","unstructured":"Sasson SC, McGill K, Wienholt L, Carr A, Brown DA, Kelleher AD, et al. Comparison of the Freelite serum free light chain (SFLC) assay with serum and urine electrophoresis\/immunofixation and the N Latex FLC assay. Pathology. 2015;47(6):564\u20139. https:\/\/doi.org\/10.1097\/PAT.0000000000000316.","journal-title":"Pathology"},{"issue":"25","key":"1090_CR22","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1200\/JCO.2013.50.0892","volume":"32","author":"BM Weiss","year":"2014","unstructured":"Weiss BM, Hebreo J, Cordaro DV, Roschewski MJ, Baker TP, Abbott KC, et al. Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis. J Clin Oncol. 2014;32(25):2699\u2013704. https:\/\/doi.org\/10.1200\/JCO.2013.50.0892.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1090_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3760\/cma.j.issn.0253-2727.2019.04.011","volume":"40","author":"L Li","year":"2019","unstructured":"Li L, Jiang H, Fu WJ, Du J, He HY, Lu J, et al. Evaluation and comparison of prognostic value of serum free light chain ratio\/difference in patients with newly diagnosed multiple myeloma. Zhonghua Xue Ye Xue Za Zhi. 2019;40(4):321\u20136. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2019.04.011. (Chinese).","journal-title":"Zhonghua Xue Ye Xue Za Zhi."},{"issue":"1","key":"1090_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/bmt.2015.164","volume":"51","author":"AM Sherrod","year":"2016","unstructured":"Sherrod AM, Hari P, Mosse CA, Walker RC, Cornell RF. Minimal residual disease testing after stem cell transplantation for multiple myeloma. Bone Marrow Transplant. 2016;51(1):2\u201312.","journal-title":"Bone Marrow Transplant"},{"issue":"04","key":"1090_CR25","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.19746\/j.cnki.issn1009-2137.2020.04.027","volume":"28","author":"ZQ Li","year":"2020","unstructured":"Li ZQ, Tian WW, Guo YF, Ma LM. Impact of serum free light chain ratio and normalization ratio after treatment on diagnosis and prognosis of newly diagnosed multiple myeloma patients. J Exp Hematol China. 2020;28(04):1245\u201350. https:\/\/doi.org\/10.19746\/j.cnki.issn1009-2137.2020.04.027.","journal-title":"J Exp Hematol China"},{"issue":"4","key":"1090_CR26","first-page":"87","volume":"35","author":"D Huo","year":"2020","unstructured":"Huo D, Qin S, Wu YC, Liu Y, Xing RQ, Peng DR, et al. Clinical value exploration on detection of serum total light chain and free light chain in the diagnosis of multiple myeloma. J Mod Lab Med. 2020;35(4):87\u20138.","journal-title":"J Mod Lab Med."},{"issue":"12","key":"1090_CR27","doi-asserted-by":"publisher","first-page":"939","DOI":"10.13201\/j.issn.1004-2806-b.2018.12","volume":"31","author":"JC Lu","year":"2018","unstructured":"Lu JC, Huang SJ, Tian XL, Zhou XF, Mo Y, Yao X. Application value of serum free light chain detection in multiple myeloma. J Clin Hematol. 2018;31(12):939\u201341. https:\/\/doi.org\/10.13201\/j.issn.1004-2806-b.2018.12.","journal-title":"J Clin Hematol"},{"issue":"1","key":"1090_CR28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.19746\/j.cnki.issn.1009-2137.2020.01.032","volume":"28","author":"XN Jiang","year":"2020","unstructured":"Jiang XN, Chen JF, Wang Y. Value of serum free light chain kappa\/lambda ratio detection combined with immunofixation electrophoresis in the prognosis evaluation of patients with multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020;28(1):191\u20135. https:\/\/doi.org\/10.19746\/j.cnki.issn.1009-2137.2020.01.032. (Chinese).","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi."},{"issue":"5","key":"1090_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3760\/cma.j.issn0253-2727.2016.05.005","volume":"37","author":"PF Wang","year":"2016","unstructured":"Wang PF, Xu Y, Yan S. Role of serum free light chain \u03ba\/\u03bb ratio in diagnosis and prognosis of newly diagnosed multiple myeloma patients. Chin J Hematol. 2016;37(5):377\u201382. https:\/\/doi.org\/10.3760\/cma.j.issn0253-2727.2016.05.005.","journal-title":"Chin J Hematol"},{"issue":"11","key":"1090_CR30","doi-asserted-by":"publisher","first-page":"848","DOI":"10.13602\/j.cnki.jcls.2019.11.10","volume":"37","author":"WT Qiang","year":"2019","unstructured":"Qiang WT, Luo TC, Lu J. Prognostic value of serum free light chain ratio in newly diagnosed multiple myeloma. J Clin Lab Sci Med. 2019;37(11):848\u201352. https:\/\/doi.org\/10.13602\/j.cnki.jcls.2019.11.10.","journal-title":"J Clin Lab Sci Med"},{"issue":"3","key":"1090_CR31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1615\/CritRevImmunol.2019032260","volume":"39","author":"AA Ansari","year":"2019","unstructured":"Ansari AA, Tipu HN, Ahmed D, Farhan M. Evaluation of serum free light chain in diagnosis and monitoring of plasma cell disorders. Crit Rev Immunol. 2019;39(3):203\u201310. https:\/\/doi.org\/10.1615\/CritRevImmunol.2019032260.","journal-title":"Crit Rev Immunol"},{"issue":"8","key":"1090_CR32","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1373\/clinchem.2018.299461","volume":"65","author":"L Sepiashvili","year":"2019","unstructured":"Sepiashvili L, Kohlhagen MC, Snyder MR, Willrich MA, Mills JR, Dispenzieri A, Murray DL. Direct detection of monoclonal free light chains in serum by use of immunoenrichment-coupled MALDI-TOF mass spectrometry. Clin Chem. 2019;65(8):1015\u201322. https:\/\/doi.org\/10.1373\/clinchem.2018.299461.","journal-title":"Clin Chem."},{"issue":"7","key":"1090_CR33","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1182\/blood-2015-04-638742","volume":"126","author":"J Mart\u00ednez-L\u00f3pez","year":"2015","unstructured":"Mart\u00ednez-L\u00f3pez J, Paiva B, L\u00f3pez-Anglada L, Mateos MV, Cedena T, Vidr\u00edales MB, et al. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Blood. 2015;126(7):858\u201362. https:\/\/doi.org\/10.1182\/blood-2015-04-638742.","journal-title":"Blood"},{"issue":"23","key":"1090_CR34","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood.V126.23.2962.2962","volume":"126","author":"L Lopezanglada","year":"2015","unstructured":"Lopezanglada L, Cuetofelgueroso C, Mateos MV, Rosi\u00f1ol L, Oriol A, Teruel AI, et al. Usefulness of serum-free-light-chains-ratio (SFLCR) and serum heavy-light-chains-ratio (SHLCR) in multiple myeloma in the context of three GEM\/Pethema clinical trials. Blood. 2015;126(23):2962.","journal-title":"Blood"},{"issue":"6","key":"1090_CR35","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.2215\/CJN.02290508","volume":"3","author":"CA Hutchison","year":"2008","unstructured":"Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(6):1684\u201390. https:\/\/doi.org\/10.2215\/CJN.02290508.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"25","key":"1090_CR36","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","volume":"35","author":"JJ Lahuerta","year":"2017","unstructured":"Lahuerta JJ, Paiva B, Vidriales MB, Cord\u00f3n L, Cedena MT, Puig N, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials. J Clin Oncol. 2017;35(25):2900\u201310. https:\/\/doi.org\/10.1200\/JCO.2016.69.2517.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1090_CR37","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1007\/s10147-019-01436-8","volume":"24","author":"K Sunami","year":"2019","unstructured":"Sunami K, Matsumoto M, Fuchida SI, Omoto E, Takamatsu H, Adachi Y, et al. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan study group for cell therapy and transplantation (JSCT-MM12). Int J Clin Oncol. 2019;24(8):966\u201375. https:\/\/doi.org\/10.1007\/s10147-019-01436-8.","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"1090_CR38","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/cncr.31854","volume":"125","author":"M Gambella","year":"2019","unstructured":"Gambella M, Omed\u00e9 P, Spada S, Muccio VE, Gilestro M, Saraci E, et al. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: a pooled analysis. Cancer. 2019;125(5):750\u201360. https:\/\/doi.org\/10.1002\/cncr.31854.","journal-title":"Cancer"},{"issue":"8","key":"1090_CR39","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","volume":"130","author":"A Chari","year":"2017","unstructured":"Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma. Blood. 2017;130(8):974\u201381. https:\/\/doi.org\/10.1182\/blood-2017-05-785246.","journal-title":"Blood"},{"issue":"1","key":"1090_CR40","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/j.seminhematol.2018.03.001","volume":"55","author":"O Landgren","year":"2018","unstructured":"Landgren O, Lu SX, Hultcrantz M. MRD testing in multiple myeloma: the main future driver for modern tailored treatment. Semin Hematol. 2018;55(1):44\u201350. https:\/\/doi.org\/10.1053\/j.seminhematol.2018.03.001.","journal-title":"Semin Hematol"},{"issue":"15","key":"1090_CR41","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1158\/1078-0432.CCR-16-2895","volume":"23","author":"KC Anderson","year":"2017","unstructured":"Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, et al. The role of minimal residual disease testing in myeloma treatment selection and drug development: current value and future applications. Clin Cancer Res. 2017;23(15):3980\u201393. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2895.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1090_CR42","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3760\/cma.j.cn112138-20200304-00179","volume":"59","author":"Chinese Hematology Association; Chinese Society of Hematology; Chinese Myeloma Committee-Chinese Hematology Association","year":"2020","unstructured":"Chinese Hematology Association; Chinese Society of Hematology; Chinese Myeloma Committee-Chinese Hematology Association. The guidelines for the diagnosis and management of multiple myeloma in China (2020 revision). Zhonghua Nei Ke Za Zhi. 2020;59(5):341\u20136. https:\/\/doi.org\/10.3760\/cma.j.cn112138-20200304-00179. (Chinese).","journal-title":"Zhonghua Nei Ke Za Zhi."},{"issue":"5","key":"1090_CR43","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3760\/cma.j.cn112138-20200217-00084","volume":"59","author":"YJ Chang","year":"2020","unstructured":"Chang YJ, Chen SN. Interpretation of minimal residual disease monitoring for response evaluation in \u201cthe guidelines for the diagnosis and management of multiple myeloma in China (2020 revision).\u201d Zhonghua Nei Ke Za Zhi. 2020;59(5):332\u20134. https:\/\/doi.org\/10.3760\/cma.j.cn112138-20200217-00084.","journal-title":"Zhonghua Nei Ke Za Zhi."},{"issue":"2","key":"1090_CR44","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3390\/jcm9020552","volume":"9","author":"G Di Lernia","year":"2020","unstructured":"Di Lernia G, Leone P, Solimando AG, et al. Bortezomib treatment modulates autophagy in multiple myeloma. J Clin Med. 2020;9(2):552.","journal-title":"J Clin Med."}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01090-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-024-01090-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01090-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T02:16:28Z","timestamp":1718417788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-024-01090-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1090"],"URL":"https:\/\/doi.org\/10.1007\/s12672-024-01090-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,15]]},"assertion":[{"value":"4 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval and consent were not required as this study was based on publicly available data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"229"}}